Literature DB >> 18596953

Diabetes care - insulin delivery in a changing world.

Alan Marcus1.   

Abstract

Controlling blood glucose levels within acceptable limits is crucial to the long-term health of patients with type 2 diabetes, and patient involvement is a vital element in achieving this goal. The benefits of patient education and chronic disease management tools cannot be underestimated as many patients will require initiation of insulin therapy to achieve glycemic targets. The wide choice of insulin formulations and the ever-expanding range of delivery methods now available make insulin administration easier, less painful, more discreet, and more accurate than ever before, thus providing important tools to overcome barriers to insulin initiation and improve achievement of glycemic goals. In addition, exciting developments in technology for self-monitoring of blood glucose have increased the potential for optimal glycemic control. This review discusses how these approaches can help patients manage their diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18596953      PMCID: PMC2438492     

Source DB:  PubMed          Journal:  Medscape J Med        ISSN: 1934-1997


  78 in total

1.  Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies.

Authors:  Richard R Rubin; Mark Peyrot
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

Review 2.  Continuous glucose monitoring: roadmap for 21st century diabetes therapy.

Authors:  David C Klonoff
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

3.  Standards of medical care in diabetes--2007.

Authors: 
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

Review 4.  Appropriate use of insulin analogs in an increasingly complex type 2 diabetes mellitus (T2DM) landscape.

Authors:  Thomas M Flood
Journal:  J Fam Pract       Date:  2007-01       Impact factor: 0.493

5.  Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials.

Authors:  John Pickup; Martin Mattock; Sally Kerry
Journal:  BMJ       Date:  2002-03-23

6.  Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

Authors:  J Rosenstock; S L Schwartz; C M Clark; G D Park; D W Donley; M B Edwards
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

7.  Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change.

Authors:  Richard W Grant; John B Buse; James B Meigs
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

8.  Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.

Authors:  Won Chan Lee; Sanjeev Balu; David Cobden; Ashish V Joshi; Chris L Pashos
Journal:  Clin Ther       Date:  2006-10       Impact factor: 3.393

Review 9.  Overcoming obstacles: collaboration for change.

Authors:  M M Funnell
Journal:  Eur J Endocrinol       Date:  2004-10       Impact factor: 6.664

10.  Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents.

Authors:  Jaime Guevara-Aguirre; Marco Guevara; Jeannette Saavedra; Marko Mihic; Pankaj Modi
Journal:  Diabetes Technol Ther       Date:  2004-02       Impact factor: 6.118

View more
  10 in total

1.  Evaluating the Impact of Human Factors and Pen Needle Design on Insulin Pen Injection.

Authors:  Christopher Rini; Bruce C Roberts; Didier Morel; Rick Klug; Benjamin Selvage; Ronald J Pettis
Journal:  J Diabetes Sci Technol       Date:  2019-03-17

2.  Functional Evaluation of the Reusable JuniorSTAR® Half-Unit Insulin Pen.

Authors:  David Klonoff; Irina Nayberg; Ivana Rabbone; Catherine Domenger; Udo Stauder; Hamid Oualali; Thomas Danne
Journal:  J Diabetes Sci Technol       Date:  2015-01-28

Review 3.  Evolution of diabetes insulin delivery devices.

Authors:  Jean-Louis Selam
Journal:  J Diabetes Sci Technol       Date:  2010-05-01

Review 4.  Practical aspects of insulin pen devices.

Authors:  Teresa L Pearson
Journal:  J Diabetes Sci Technol       Date:  2010-05-01

5.  Does Device Make Any Difference? A Real-world Retrospective Study of Insulin Treatment Among Elderly Patients With Type 2 Diabetes.

Authors:  Raymond Miao; Wenhui Wei; Jay Lin; Lin Xie; Onur Baser
Journal:  J Diabetes Sci Technol       Date:  2014-01-01

6.  Impact of Injection Speed, Volume, and Site on Pain Sensation.

Authors:  Eric Zijlstra; Johannes Jahnke; Annelie Fischer; Christoph Kapitza; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2017-10-08

Review 7.  Insulin delivery methods: Past, present and future.

Authors:  Rima B Shah; Manhar Patel; David M Maahs; Viral N Shah
Journal:  Int J Pharm Investig       Date:  2016 Jan-Mar

Review 8.  The Review of Insulin Pens-Past, Present, and Look to the Future.

Authors:  Małgorzata Masierek; Katarzyna Nabrdalik; Oliwia Janota; Hanna Kwiendacz; Maksymilian Macherski; Janusz Gumprecht
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-08       Impact factor: 5.555

9.  Development of an Insulin Pen is a Patient-Centric Multidisciplinary Undertaking: A Commentary.

Authors:  Thomas Sparre; Niels-Aage B Hansen; Anya Sonia Wernersson; Mark Guarraia
Journal:  J Diabetes Sci Technol       Date:  2021-12-01

10.  Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.

Authors:  Stephen C L Gough; Anuj Bhargava; Rajeev Jain; Henriette Mersebach; Søren Rasmussen; Richard M Bergenstal
Journal:  Diabetes Care       Date:  2013-05-28       Impact factor: 19.112

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.